Showing 1551-1560 of 1746 results for "".
- Gyroscope Therapeutics Granted FDA Fast Track Designation for Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-granted-fda-fast-track-designation-for-investigational-gene-therapy-for-dry-amd/2478305/Gyroscope Therapeutics announced that the FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is i
- Aura Biosciences Doses First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanomahttps://modernod.com/news/aura-biosciences-doses-first-patient-in-phase-2-study-evaluating-suprachoroidal-administration-of-au-011-in-patients-with-choroidal-melanoma/2478272/Aura Biosciences announced the dosing of the first patient in a phase 2 study evaluating the safety and efficacy of suprachoroidal (SC) administration of AU-011, the company’s lead product candidate, as a potential first-line treatment for patients with primary choroidal melanoma. “I am ho
- Graybug Vision Appoints Robert Breuil as Chief Financial Officerhttps://modernod.com/news/graybug-vision-appoints-robert-breuil-as-chief-financial-officer/2478245/Graybug Vision announced the appointment of Robert S. Breuil as chief financial officer, effective immediately. Mr. Breuil succeeds Daniel Geffken, founder and managing director of Danforth Advisors, who led the function as ad-interim CFO. “I am excited to welcome Robert Breuil to the Gray
- FDA Approves Cystadrops for the Ocular Manifestations of Cystinosishttps://modernod.com/news/fda-approves-cystadrops-for-the-ocular-manifestations-of-cystinosis/2478201/Recordati Rare Diseases announced the FDA has approved Cystadrops (cysteamine ophthalmic solution 0.37%), a new, viscous eye drop solution that depletes corneal cystine crystal deposits in people living with cystinosis. Cystadrops demonstrated a significant reduction in cystine crystal deposits i
- OCT Angiography a Good Way to Detect Diabetic Retinopathyhttps://modernod.com/news/oct-angiography-a-good-way-to-detect-diabetic-retinopathy/2478091/Wide-field swept-source optical coherence tomography angiography (WF OCTA) can detect diabetic retinopathy as well as fluorescein angiography and ultrawide-field color fundus photography, according to results from two analyses, as report i
- Reopen Eyecare Website Launches Todayhttps://modernod.com/news/reopen-eyecare-website-launches-today/2477805/Reopeneyecare.com, a new digital platform designed to help eyecare providers navigate the implications of the COVID-19 pandemic on their businesses, launched today. Featuring content specially curated by a taskforce of vision community leaders and sponsored by The Vision Council, the website is i
- Regeneron CEO: Manufacturing Not Up to Snuff for COVID-19 Vaccines, Therapieshttps://modernod.com/news/regeneron-ceo-manufacturing-not-up-to-snuff-for-covid-19-vaccines-therapies/2477753/Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can’t produce a therapy or vaccine fast enough—and the company’s helmsman i
- Alimera Sciences Pre-Announces Expected Topline Revenue for Q1 2020 and Provides COVID-19 Business Updatehttps://modernod.com/news/alimera-sciences-pre-announces-expected-topline-revenue-for-q1-2020-and-provides-covid-19-business-update/2477586/Alimera Sciences announced topline revenue guidance for the quarter ending March 31, 2020. Alimera expects to report consolidated net revenue for the first quarter of 2020 exceeding $14 million, which compares to $12.9 million in the first quarter of 2019. Additionally, the company strengthened i
- Breakthrough Technology Used to Discover Eye Damage from Repeated Intravitreal Injectionshttps://modernod.com/news/breakthrough-technology-used-to-discover-eye-damage-from-repeated-intravitreal-injections/2477567/In a first of its kind study, Mount Sinai researchers are using optimal coherence tomography angiography (OCTA) to measure potential retina damage from long-term use of intravitreal eye injections. The findings, published in the April issue of Retina, suggest that repeated use of these i
- US Department of Labor Provides Guidance on Paid Sick and Family Leavehttps://modernod.com/news/us-department-of-labor-provides-guidance-on-paid-sick-and-family-leave/2477487/The Department of Labor just updated its ‘Questions and Answers’ on paid sick and family leave during the COVID-19 pandemic. This includes guidance on: (i) teleworking, furloughs, layoffs, reduced schedules, and office closures (employees are not eligible for paid sick o